Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle | The
BMJ Skip to main content Intended for healthcare professionals Access provided by Google …

There is increasing discussion in public and academic forums about the anticipated benefits
of pharmacogenomics, as well as the attendant social and ethical implications of this …

Like most publications on a new subject and unexplored issues, this book is the result of a
collective enterprise. It benefited from fruitful collaboration between individuals and support …

As markets become more dynamic and competitive, companies must reconsider how they
view inventory and make changes to their production and inventory systems. They must …

In this article the authors provide insight into the basis for price setting of medicines, the
increasing pharmaceutical budgets in the past decades, and the measures governments …

Fundamentos: el objetivo del trabajo es es conocer si el impacto del Real Decreto-Ley
16/2012 en el número de recetas y el gasto farmacéutico, evaluadas por el Ministerio de …

Background Controlling the growth of pharmaceutical expenditures is a major global
challenge. Promotion of generic drug prescriptions or use is gaining increased support …

Objective Our objective is to review and assess the main pharmaceutical cost-containment
policies used in Ireland in recent years, and to highlight how a policy that improved fiscal …

The social problem of unreasonably high pharmaceutical costs for patients in Chinese
hospitals damages the interests of patients and it has a highly negative impact on the long …

Background Despite the potential widespread application and a significant need, the policy
effectiveness of prescribed medications price controls has not been studied extensively. We …